By Nana O 
Cambridge, UK – In a significant advancement that challenges long-held assumptions about the permanence of nerve damage, scientists at the University of Cambridge have developed sophisticated lab-grown brain and spinal cord systems that meticulously replicate the intricate pathways of human motor control. This pioneering research, detailed in the latest issue of Cell Reports, has unveiled compelling evidence suggesting that nerve damage, once considered irreversible, may possess a remarkable capacity for regeneration under specific developmental conditions. The findings offer a beacon of hope for individuals living with debilitating neurological conditions and injuries.
The Intricate Dance of Neural Communication
From the earliest stages of embryonic development, the human nervous system embarks on a remarkable journey of intricate wiring. Neurons, the fundamental building blocks of this network, forge complex communication channels between the brain and the spinal cord. These vital messages, responsible for everything from simple reflexes to voluntary movement, are transmitted along axons – the long, slender projections of nerve cells that act as the conduits for electrical and chemical signals. The precise coordination of these axonal pathways is paramount to our ability to interact with and navigate the world.
However, a critical biological shift occurs as the central nervous system matures. In adulthood, the remarkable regenerative capacity observed in developing neurons largely diminishes. This inherent limitation means that injuries to the brain or spinal cord, which can disrupt these crucial axonal connections, frequently result in permanent functional deficits. Conditions such as paralysis, loss of sensation, and other severe motor impairments are often the tragic consequences of this limited regenerative potential. Furthermore, this decline in neuronal repair is also implicated in the progression of devastating neurological diseases, including motor neurone disease (MND) and multiple sclerosis (MS), conditions that progressively degrade nerve function and quality of life.
Miniature Marvels: Recreating the Central Nervous System in Vitro
The breakthrough emerged from the laboratory of Dr. András Lakatos, a leading researcher at the University of Cambridge’s Department of Clinical Neurosciences. Building upon their previous success in creating pea-sized "brain organoids" in 2021 – miniature models of the cerebral cortex derived from patient-derived stem cells – the team has now engineered a more comprehensive system. This latest research involves the creation of interconnected lab-grown brain and spinal cord models, designed to mirror the functional relationship between these two critical components of the central nervous system.
The challenge lay in replicating the distinct yet interconnected nature of the brain and spinal cord. To achieve this, the researchers maintained the brain and spinal cord organoids in separate compartments within the laboratory environment. Crucially, they observed and documented the axons extending from the brain tissue successfully bridging the physical gap to establish connections with the spinal cord tissue. The resulting neural circuitry was remarkably sophisticated, demonstrating sufficient functionality to initiate contractions in meticulously cultured clusters of muscle cells. This intricate dance between the lab-grown brain and spinal cord, culminating in observable muscle activity, serves as a powerful testament to the model’s fidelity in mimicking human neurodevelopmental processes.
A Developmental Window for Regeneration
The research team meticulously monitored these miniature human nervous system models for an extended period, exceeding one year in laboratory culture. This prolonged observation period allowed for a detailed analysis of axonal regenerative capabilities at different developmental stages. Their findings revealed a critical window of opportunity for nerve regrowth. Until approximately day 150 of development – a timeline that broadly corresponds to the mid-gestation period in human pregnancy – damaged axons exhibited a significant capacity to regrow and re-establish connections.
However, beyond this developmental milestone, the researchers observed a dramatic and precipitous decline in the neurons’ ability to regenerate. This stark contrast underscores a fundamental biological shift that occurs as the central nervous system matures.
"Neurons taken from less mature organoids regrew long fibers after injury, but those from more mature organoids showed a sharp drop in their ability to regrow," explained George Gibbons, the first author of the study and a researcher in the Department of Clinical Neurosciences at the University of Cambridge. "In other words, poor regeneration is built into human neurons as they mature in the central nervous system." This statement highlights a key insight: the limitations on regeneration are not simply an external consequence of injury but are intrinsically programmed into neuronal development.
Unlocking the Genetic Switch for Axonal Growth
Delving deeper into the molecular mechanisms underlying this developmental shift, the scientists analyzed gene activity within the neurons responsible for connecting the brain and spinal cord. Their comprehensive analysis identified a complex network of genes that appears to function as a biological "switch." As neurons mature and establish synaptic connections, this genetic network actively limits further axon growth. This regulatory mechanism, while essential for forming a stable and organized nervous system, inadvertently hinders the regenerative potential of axons after injury.
Perhaps the most electrifying discovery of the study came with the experimental manipulation of this genetic network. By strategically blocking key regulatory components within this identified network, the researchers were able to observe a remarkable reversal: the mature neurons regained their capacity for robust axon growth. This intervention demonstrated that the decline in regeneration is not an immutable biological fate but rather a process that can potentially be modulated.
A Pharmaceutical Ally in Nerve Repair
Prompted by the identification of this critical gene network, the Cambridge team embarked on a further investigation to identify existing pharmaceutical compounds that might influence its activity. They scoured a comprehensive database of drug compounds, seeking molecules known to interact with the genes implicated in limiting axon growth. Among the promising candidates, one compound stood out: lynestrenol.
Lynestrenol is a synthetic progestogen hormone drug that is already approved for medical use, primarily for managing certain menstrual disorders and as a component of contraceptive therapies. Its established safety profile in humans, coupled with its demonstrated interaction with the identified gene network, made it a compelling subject for further testing in the context of nerve regeneration.
When lynestrenol was administered to damaged neurons in the lab-grown models, the results were striking. The drug significantly enhanced axonal regrowth, effectively counteracting the developmental limitations previously observed. This finding provides a tangible, albeit early, lead for therapeutic intervention.
The researchers acknowledged that factors beyond intrinsic neuronal limitations, such as the formation of scar tissue and ongoing inflammation at injury sites, can also impede nerve repair. However, they emphasized the critical importance of understanding the neuron-specific biological mechanisms that restrict regeneration. Previous research has indicated that younger neurons can navigate and grow through environments that typically inhibit repair in adult nervous systems, suggesting that targeting the intrinsic regenerative capacity of neurons themselves is a crucial avenue for exploration.
Dr. Lakatos elaborated on the implications of these findings: "When the brain and spinal cord are damaged, the nerve fibers that carry movement signals from the brain to the spinal cord rarely grow back. That’s why paralysis is usually permanent. But we didn’t know exactly when the ability of axons to regenerate becomes limited. Our model provides a good indication that this block happens during development, and it can still be reversed after this point."
He continued, "Lynestrenol itself may not be the answer to spinal cord repair, but it shows us that, in principle, it should be possible to directly target human neurons and regenerate their axons. Although we still need to show that this strategy will also help to re-establish appropriate connections between the brain and spinal cord cells, this gives us hope that one day we may be able to treat conditions previously thought untreatable." This measured optimism underscores the scientific rigor of the research while acknowledging the significant work that lies ahead.
The Growing Importance of Human Organoids in Medical Research
The success of this study is intrinsically linked to the burgeoning field of organoid technology. Human organoids, miniature, self-organizing three-dimensional tissues grown in vitro, are revolutionizing our ability to study human biology and disease. While animal models, such as mice and rats, have historically been indispensable tools in biomedical research, significant biological differences between species can limit the direct translation of findings to human patients.
Human stem cell-derived organoids, like those developed by Dr. Lakatos’s team, offer a more accurate and relevant platform for investigating human-specific biological processes. They provide an unprecedented opportunity to bridge the gap between findings in animal models and the actual clinical outcomes observed in human patients.
"Much of what we know about nerve regeneration comes from rodents, whose neurons behave differently from human neurons," Dr. Lakatos noted. "Our sophisticated organoid models help bridge the knowledge gap from animal models to what we see in patients. They are also an important contribution to efforts to reduce the use of animals in research." This statement highlights the ethical and scientific advantages of employing human organoids, aligning with global efforts to refine, reduce, and replace animal testing in research.
The University of Cambridge is at the forefront of utilizing organoid technology across a diverse range of medical disciplines. Researchers are employing these advanced models to investigate strategies for repairing damaged livers, unraveling the complexities of Crohn’s disease in children, and studying the critical early stages of human pregnancy. The potential applications of organoid technology are vast and continue to expand as scientists refine their techniques and understanding.
This groundbreaking research was generously supported by funding from UK Research and Innovation (UKRI) through the Medical Research Council (MRC) and the charity Spinal Research, underscoring the collaborative and multi-faceted support crucial for advancing complex scientific endeavors. The findings from Cambridge represent a significant leap forward, offering a renewed sense of possibility in the quest to restore function and improve the lives of those affected by neurological damage and disease.
